drugset / Trial / NCT05433272
Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated
Phase 3
Unknown
1400 enrolled
Sinovac Biotech (Colombia) S.A.S.
Sinovac Life Sciences Co., Ltd. · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a randomized, double-blind, active-controlled phase Ⅲ clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of one booster dose of trivalent COVID-19 vaccine (vero cell), inactivated, prototype strain, delta strain and omicron strain in healthy people aged 3 years old and above and have completed two or three doses of CoronaVac® in Colombia.
Timeline
- Start
- 2023-08-10
- Primary completion
- 2023-09-10
- Completion
- 2023-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CoronaVac | Vaccine | 3 ug | Intramuscular |
| Subject | Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain | Vaccine | 18 ug | Intramuscular |